

Bruce L. Innis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3235230/publications.pdf>

Version: 2024-02-01

132
papers

9,472
citations

44444

50
h-index

46524

93
g-index

137
all docs

137
docs citations

137
times ranked

7600
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. <i>EClinicalMedicine</i> , 2022, 45, 101323.	3.2	26
2	Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1–2 randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1062-1075.	4.6	10
3	Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. <i>Vaccine</i> , 2022, 40, 3621-3632.	1.7	15
4	A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. <i>Nature Medicine</i> , 2021, 27, 106-114.	15.2	204
5	Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model. <i>Vaccines</i> , 2021, 9, 40.	2.1	14
6	AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets. <i>Npj Vaccines</i> , 2021, 6, 40.	2.9	8
7	Immunogenicity and Safety of AS03-adjuvanted H5N1 Influenza Vaccine in Children 6–35 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, e333-e339.	1.1	8
8	Historical Analysis of the Risk of Hepatitis E and Its Complications in Pregnant Women in Nepal, 1996–1998. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 440-448.	0.6	1
9	A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. <i>Nature Communications</i> , 2021, 12, 6197.	5.8	61
10	Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 80-91.	4.6	103
11	Evaluation of a New Clinical Endpoint for Moderate to Severe Influenza Disease in Children: A Prospective Cohort Study. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 460-467.	0.6	6
12	Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e1-e10.	1.1	23
13	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2020, 8, 771.	2.1	61
14	Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting. <i>Vaccine</i> , 2020, 38, 2435-2448.	1.7	54
15	Convening on the influenza human viral challenge model for universal influenza vaccines, Part 2: Methodologic considerations. <i>Vaccine</i> , 2019, 37, 4830-4834.	1.7	10
16	Meeting report: Convening on the influenza human viral challenge model for universal influenza vaccines, Part 1: Value; challenge virus selection; regulatory, industry and ethical considerations; increasing standardization, access and capacity. <i>Vaccine</i> , 2019, 37, 4823-4829.	1.7	14
17	Safety of AS03-adjuvanted influenza vaccines: A review of the evidence. <i>Vaccine</i> , 2019, 37, 3006-3021.	1.7	72
18	Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2090-2105.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts. <i>Npj Vaccines</i> , 2019, 4, 51.	2.9	18
20	Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 203-210.	1.1	2
21	Clinical Presentation of Influenza in Children 6 to 35 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 866-872.	1.1	17
22	Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice. <i>ImmunoHorizons</i> , 2019, 3, 133-148.	0.8	33
23	Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults. <i>BMC Infectious Diseases</i> , 2018, 18, 186.	1.3	5
24	Prevention of vaccine-matched and mismatched influenza in children aged 6–35 months: a multinational randomised trial across five influenza seasons. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 338-349.	2.7	51
25	Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. <i>Vaccine</i> , 2018, 36, 3411-3417.	1.7	52
26	Immunization against Hepatitis E. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a032573.	2.9	19
27	Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 1435-1443.	0.6	31
28	Reactogenicity and safety of AS03B-adjuvanted H5N1 influenza vaccine in children: an open-label, one-way, crossover trial. <i>Asian Biomedicine</i> , 2018, 11, 359-364.	0.2	0
29	Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, piw068.	0.6	16
30	Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial. <i>Vaccine</i> , 2017, 35, 1431-1439.	1.7	11
31	Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1516-1522.	1.4	10
32	A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1640-1652.	1.4	42
33	Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65 years of age and older: A phase II, observer-blind, randomized, controlled trial. <i>Vaccine</i> , 2017, 35, 1865-1872.	1.7	13
34	Evaluation of a primary course of H9N2 vaccine with or without AS03 adjuvant in adults: A phase I/II randomized trial. <i>Vaccine</i> , 2017, 35, 4621-4628.	1.7	11
35	Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 1325-1337.	0.6	50
36	A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. <i>Npj Vaccines</i> , 2016, 1, .	2.9	65

#	ARTICLE	IF	CITATIONS
37	Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 1348-1358.	0.6	5
38	Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults. <i>Journal of Infectious Diseases</i> , 2016, 214, 1717-1727.	1.9	46
39	Evaluation of potential immunogenicity differences between <i>Pandemrix</i> and <i>Arepanrix</i> . <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2289-2298.	1.4	10
40	Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines. <i>Expert Review of Vaccines</i> , 2016, 15, 201-214.	2.0	17
41	Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6–35 Months of Age During 2013–2014: Results From A Phase II Randomized Trial. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2016, 5, 170-179.	0.6	25
42	Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012–2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 242-251.	0.6	28
43	Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv067.	0.4	39
44	AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes. <i>Vaccine</i> , 2015, 33, 3784-3787.	1.7	9
45	An Adjuvanted, Tetravalent Dengue Virus Purified Inactivated Vaccine Candidate Induces Long-Lasting and Protective Antibody Responses Against Dengue Challenge in Rhesus Macaques. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 698-708.	0.6	51
46	Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial. <i>Journal of Infectious Diseases</i> , 2015, 212, 531-541.	1.9	16
47	A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 441-453.	0.6	32
48	AS03B-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial. <i>Journal of Infectious Diseases</i> , 2015, 211, 801-810.	1.9	21
49	Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 339-348.	0.6	18
50	Vaccine for Prevention of Influenza in Children. <i>New England Journal of Medicine</i> , 2014, 370, 1167-1168.	13.9	2
51	Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2942-2957.	1.4	22
52	Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines. <i>Influenza and Other Respiratory Viruses</i> , 2014, 8, 452-462.	1.5	24
53	Immunogenicity and Safety of Inactivated Quadrivalent and Trivalent Influenza Vaccines in Children 18–47 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 1262-1269.	1.1	18
54	Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 545-557.	1.9	32

#	ARTICLE	IF	CITATIONS
55	A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine. <i>BMC Infectious Diseases</i> , 2014, 14, 133.	1.3	7
56	Safety and Immunogenicity of a Rederived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults Living in Thailand: A Randomized Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 119-128.	0.6	38
57	Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: A phase III, randomized trial. <i>Vaccine</i> , 2014, 32, 1480-1487.	1.7	70
58	Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. <i>Lancet</i> , The, 2014, 383, 1313-1324.	6.3	83
59	AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 485-496.	4.6	143
60	Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. <i>BMC Infectious Diseases</i> , 2013, 13, 343.	1.3	95
61	A model international partnership for community-based research on vaccine-preventable diseases: The Kamphaeng Phet-AFRIMS Virology Research Unit (KAVRU). <i>Vaccine</i> , 2013, 31, 4487-4500.	1.7	7
62	Experimental Dengue Virus Challenge of Human Subjects Previously Vaccinated With Live Attenuated Tetravalent Dengue Vaccines. <i>Journal of Infectious Diseases</i> , 2013, 207, 700-708.	1.9	74
63	A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 73-88.	0.6	86
64	Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children. <i>Journal of Infectious Diseases</i> , 2013, 208, 544-553.	1.9	62
65	Vaccine for Prevention of Mild and Moderate-to-Severe Influenza in Children. <i>New England Journal of Medicine</i> , 2013, 369, 2481-2491.	13.9	124
66	A Randomized Trial of Candidate Inactivated Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccines in Children Aged 3-17 Years. <i>Journal of Infectious Diseases</i> , 2013, 207, 1878-1887.	1.9	97
67	Immunogenicity and Safety of Two Tetravalent (Measles, Mumps, Rubella, Varicella) Vaccines Coadministered With Hepatitis A and Pneumococcal Conjugate Vaccines to Children Twelve to Fourteen Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, e133-e140.	1.1	23
68	Interference and Facilitation Between Dengue Serotypes in a Tetravalent Live Dengue Virus Vaccine Candidate. <i>Journal of Infectious Diseases</i> , 2011, 204, 442-450.	1.9	40
69	Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine. <i>Hum Vaccin</i> , 2011, 7, 81-88.	2.4	7
70	Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine in Flavivirus-Naive Infants. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 85, 341-351.	0.6	67
71	A Phase III Evaluation of Immunogenicity and Safety of Two Trivalent Inactivated Seasonal Influenza Vaccines in US Children. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 924-930.	1.1	21
72	Genetic characterization of early isolates of Japanese encephalitis virus: genotype II has been circulating since at least 1951. <i>Journal of General Virology</i> , 2010, 91, 95-102.	1.3	40

#	ARTICLE	IF	CITATIONS
73	Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. <i>Hum Vaccin</i> , 2009, 5, 33-40.	2.4	110
74	Efficacy of Inactivated Split-Virus Influenza Vaccine against Culture-Confirmed Influenza in Healthy Adults: A Prospective, Randomized, Placebo-Controlled Trial. <i>Journal of Infectious Diseases</i> , 2009, 200, 1861-1869.	1.9	55
75	Safety and Immunogenicity of a Tetravalent Live-attenuated Dengue Vaccine in Flavivirus Naive Children. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 78, 426-433.	0.6	84
76	Comparative Evaluation of Three Assays for Measurement of Dengue Virus Neutralizing Antibodies. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 79, 115-122.	0.6	58
77	Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 78, 426-33.	0.6	39
78	Safety and Efficacy of a Recombinant Hepatitis E Vaccine. <i>New England Journal of Medicine</i> , 2007, 356, 895-903.	13.9	478
79	Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis. <i>New England Journal of Medicine</i> , 2006, 354, 11-22.	13.9	1,677
80	Hepatitis E antibody kinetics in Nepalese patients. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2006, 100, 938-941.	0.7	54
81	Protection of Rhesus Monkeys against Dengue Virus Challenge after Tetravalent Live Attenuated Dengue Virus Vaccination. <i>Journal of Infectious Diseases</i> , 2006, 193, 1658-1665.	1.9	84
82	Evidence that Rodents Are a Reservoir of Hepatitis E Virus for Humans in Nepal. <i>Journal of Clinical Microbiology</i> , 2006, 44, 1208-1208.	1.8	10
83	Comparative Evaluation of Safety and Immunogenicity of Two Dosages of an Oral Live Attenuated Human Rotavirus Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, 481-488.	1.1	94
84	Rapid Licensure of a New, Inactivated Influenza Vaccine in the United States. <i>Hum Vaccin</i> , 2005, 1, 239-244.	2.4	22
85	Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. <i>Vaccine</i> , 2005, 23, 4110-4119.	1.7	45
86	An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. <i>Vaccine</i> , 2005, 23, 4442-4452.	1.7	131
87	Rapid Detection of Adenovirus in Throat Swab Specimens by PCR during Respiratory Disease Outbreaks among Military Recruits. <i>Journal of Clinical Microbiology</i> , 2003, 41, 810-812.	1.8	49
88	SEROTYPE-SPECIFIC DENGUE VIRUS CIRCULATION AND DENGUE DISEASE IN BANGKOK, THAILAND FROM 1973 TO 1999. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 68, 191-202.	0.6	309
89	VACCINATION OF RHESUS MACAQUES AGAINST DENGUE-2 VIRUS WITH A PLASMID DNA VACCINE ENCODING THE VIRAL PRE-MEMBRANE AND ENVELOPE GENES. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 68, 469-476.	0.6	47
90	MODIFICATION OF DENGUE VIRUS STRAINS BY PASSAGE IN PRIMARY DOG KIDNEY CELLS: PREPARATION OF CANDIDATE VACCINES AND IMMUNIZATION OF MONKEYS. <i>American Journal of Tropical Medicine and Hygiene</i> , 2003, 69, 12-16.	0.6	52

#	ARTICLE	IF	CITATIONS
91	SEROTYPE-SPECIFIC TH1 RESPONSES IN RECIPIENTS OF TWO DOSES OF CANDIDATE LIVE-ATTENUATED DENGUE VIRUS VACCINES. American Journal of Tropical Medicine and Hygiene, 2003, 69, 39-47.	0.6	21
92	PHASE I TRIAL OF 16 FORMULATIONS OF A TETRAVALENT LIVE-ATTENUATED DENGUE VACCINE. American Journal of Tropical Medicine and Hygiene, 2003, 69, 48-60.	0.6	153
93	PROGRESS IN DEVELOPMENT OF A LIVE-ATTENUATED, TETRAVALENT DENGUE VIRUS VACCINE BY THE UNITED STATES ARMY MEDICAL RESEARCH AND MATERIEL COMMAND. American Journal of Tropical Medicine and Hygiene, 2003, 69, 1-4.	0.6	52
94	VACCINATION OF HUMAN VOLUNTEERS WITH MONOVALENT AND TETRAVALENT LIVE-ATTENUATED DENGUE VACCINE CANDIDATES. American Journal of Tropical Medicine and Hygiene, 2003, 69, 24-31.	0.6	128
95	Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. American Journal of Tropical Medicine and Hygiene, 2003, 68, 191-202.	0.6	177
96	Quantitation of Immunoglobulin to Hepatitis E Virus by Enzyme Immunoassay. Vaccine Journal, 2002, 9, 639-648.	3.2	27
97	Evidence that Rodents Are a Reservoir of Hepatitis E Virus for Humans in Nepal. Journal of Clinical Microbiology, 2002, 40, 4493-4498.	1.8	61
98	Clinical and Epidemiological Relevance of Quantitating Hepatitis E Virus-Specific Immunoglobulin M. Vaccine Journal, 2002, 9, 1072-1078.	3.2	32
99	Large Epidemic of Adenovirus Type 4 Infection among Military Trainees: Epidemiological, Clinical, and Laboratory Studies. Clinical Infectious Diseases, 2002, 35, 808-818.	2.9	131
100	Clinical and immunological risk factors for severe disease in Japanese encephalitis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2002, 96, 173-178.	0.7	82
101	A purified inactivated Japanese encephalitis virus vaccine made in vero cells. Vaccine, 2001, 19, 4557-4565.	1.7	90
102	Hepatitis E virus DNA vaccine elicits immunologic memory in mice. Journal of Biomedical Science, 2001, 8, 223-226.	2.6	24
103	Epidemic of adenovirus-induced respiratory illness among US military recruits: Epidemiologic and immunologic risk factors in healthy, young adults. Journal of Medical Virology, 2001, 65, 710-718.	2.5	64
104	Hepatitis B virus infection in Thai children. Tropical Medicine and International Health, 2000, 5, 633-639.	1.0	10
105	Molecular characterization of a hepatitis E virus isolate from Namibia. Journal of Biomedical Science, 2000, 7, 334-338.	2.6	24
106	Detection of Adenoviruses (AdV) in Culture-Negative Environmental Samples by PCR during an AdV-Associated Respiratory Disease Outbreak. Journal of Clinical Microbiology, 2000, 38, 2982-2984.	1.8	47
107	Phylogenetic analysis of hepatitis E virus isolates from Egypt. , 1999, 57, 68-74.		73
108	Antiserum generated by DNA vaccine binds to hepatitis E virus (HEV) as determined by PCR and immune electron microscopy (IEM): application for HEV detection by affinity-capture RT-PCR. Virus Research, 1999, 62, 59-65.	1.1	19

#	ARTICLE	IF	CITATIONS
109	Genotyping of hepatitis E virus in clinical specimens by restriction endonuclease analysis. <i>Journal of Virological Methods</i> , 1998, 70, 71-78.	1.0	23
110	Association of hepatitis E virus with an outbreak of hepatitis at a military training camp in Nepal. , 1998, 54, 178-182.		57
111	Hepatitis E virus: complete genome sequence and phylogenetic analysis of a Nepali isolate. <i>Virus Research</i> , 1998, 57, 21-26.	1.1	39
112	Rates of Hepatitis E Virus Infection and Disease among Adolescents and Adults in Kathmandu, Nepal. <i>Journal of Infectious Diseases</i> , 1997, 176, 763-766.	1.9	91
113	Hepatitis E virus in Nepal: similarities with the Burmese and Indian variants. <i>Virus Research</i> , 1997, 52, 87-96.	1.1	26
114	A putative cellular receptor for dengue viruses. <i>Nature Medicine</i> , 1997, 3, 828-829.	15.2	39
115	Identification of hepatitis E virus in clinical specimens: amplification of hydroxyapatite-purified virus RNA and restriction endonuclease analysis. <i>Journal of Virological Methods</i> , 1997, 69, 53-61.	1.0	8
116	A Cluster of Acute Hepatitis E Infection in United Nations Bangladeshi Peacekeepers in Haiti. <i>American Journal of Tropical Medicine and Hygiene</i> , 1997, 57, 449-454.	0.6	37
117	Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. <i>Vaccine</i> , 1996, 14, 329-336.	1.7	97
118	Experimental infection of the laboratory rat with the hepatitis E virus. <i>Journal of Medical Virology</i> , 1996, 48, 121-128.	2.5	118
119	11 Mechanisms of dengue virus-induced bone marrow suppression. <i>Best Practice and Research: Clinical Haematology</i> , 1995, 8, 249-270.	1.1	136
120	Antibodies that block virus attachment to vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. <i>Journal of Medical Virology</i> , 1995, 45, 451-461.	2.5	85
121	Antibody-Enhanced Binding of Dengue-2 Virus to Human Platelets. <i>Virology</i> , 1995, 213, 254-257.	1.1	113
122	Detection of Hepatitis E Virus Infections among Domestic Swine in the Kathmandu Valley of Nepal. <i>American Journal of Tropical Medicine and Hygiene</i> , 1995, 53, 228-232.	0.6	163
123	Protection Against Hepatitis A by an Inactivated Vaccine. <i>JAMA - Journal of the American Medical Association</i> , 1994, 271, 1328.	3.8	281
124	Applications of Polymerase Chain Reaction for Identification of Dengue Viruses Isolated from Patient Sera. <i>Microbiology and Immunology</i> , 1993, 37, 41-47.	0.7	30
125	High Levels of Interferon Alpha in the Sera of Children with Dengue Virus Infection. <i>American Journal of Tropical Medicine and Hygiene</i> , 1993, 48, 222-229.	0.6	112
126	Japanese Encephalitis Virus in Bangkok: Factors Influencing Vector Infections in Three Suburban Communities. <i>Journal of Medical Entomology</i> , 1992, 29, 436-444.	0.9	51

#	ARTICLE	IF	CITATIONS
127	Field efficacy trial of inactivated hepatitis A vaccine among children in Thailand (an extended) Tj ETQq1 1 0.784314,rgBT /Overlock 10	1.7	21
128	Association of hepatitis E virus with an outbreak of hepatitis in Pakistan: Serologic responses and pattern of virus excretion. Journal of Medical Virology, 1992, 36, 84-92.	2.5	75
129	Characterization of a genetic variant of human hepatitis A virus. Journal of Medical Virology, 1992, 36, 118-124.	2.5	42
130	Virus-like particles in the liver of a patient with fulminant hepatitis and antibody to hepatitis E virus. Journal of Medical Virology, 1990, 31, 229-233.	2.5	51
131	Protection against Japanese Encephalitis by Inactivated Vaccines. New England Journal of Medicine, 1988, 319, 608-614.	13.9	408
132	Virulence of a Live Dengue Virus Vaccine Candidate: A Possible New Marker of Dengue Virus Attenuation. Journal of Infectious Diseases, 1988, 158, 876-880.	1.9	83